Amaro, F.; Pisoeiro, C.; Valente, M.J.; Bastos, M.d.L.; Guedes de Pinho, P.; Carvalho, M.; Pinto, J.
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety. Int. J. Mol. Sci. 2022, 23, 9898.
https://doi.org/10.3390/ijms23179898
AMA Style
Amaro F, Pisoeiro C, Valente MJ, Bastos MdL, Guedes de Pinho P, Carvalho M, Pinto J.
Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety. International Journal of Molecular Sciences. 2022; 23(17):9898.
https://doi.org/10.3390/ijms23179898
Chicago/Turabian Style
Amaro, Filipa, Carolina Pisoeiro, Maria João Valente, Maria de Lourdes Bastos, Paula Guedes de Pinho, Márcia Carvalho, and Joana Pinto.
2022. "Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety" International Journal of Molecular Sciences 23, no. 17: 9898.
https://doi.org/10.3390/ijms23179898
APA Style
Amaro, F., Pisoeiro, C., Valente, M. J., Bastos, M. d. L., Guedes de Pinho, P., Carvalho, M., & Pinto, J.
(2022). Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety. International Journal of Molecular Sciences, 23(17), 9898.
https://doi.org/10.3390/ijms23179898